DATROWAY® Approved in Japan for HR Positive, HER2 Negative Breast Cancer

FDA Approves Injectable Form of Opdivo, Offering Greater Convenience for Cancer Patients

Reliance Acquires Oncology Platform Karkinos for ₹375 Crore

FDA Approves TEVIMBRA® for First-Line Treatment of PD-L1-Positive Gastric and Gastroesophageal Junction Cancers

CSIR's 2024 Healthcare Breakthroughs: Advancing Cancer Detection, Genetic Disorders, and Neurodegenerative Disease Research

Dr. Sandip Shah Appointed Chairman of NABL: A Visionary Leader in Indian Healthcare

Global and Indian Genetic Testing Market Trends in 2025

Mankind Pharma and Innovent Biologics Partner to Launch Groundbreaking PD-1 Immunotherapy in India

Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

Home
/
update
/
details

CSIR's 2024 Healthcare Breakthroughs: Advancing Cancer Detection, Genetic Disorders, and Neurodegenerative Disease Research

NextEdge Admin

27 Dec 2024

3 min 1 sec

Neurodegenerative Disease,Research,breast cancer,sickle cell anaemia

The Council of Scientific and Industrial Research (CSIR) made significant strides in healthcare research in 2024, with groundbreaking advancements in cancer detection, genetic disorders, and neurodegenerative diseases, as highlighted by the Ministry of Science and Technology.

In breast cancer research, the CSIR-Centre for Cellular and Molecular Biology (CSIR-CCMB) and the Regional Cancer Centre (RCC), Thiruvananthapuram, developed a low-cost, non-invasive blood test for early detection. This innovative method analyzes microRNA (miRNA) signatures, identifying 439 miRNAs associated with invasive breast cancer, including 107 biomarkers for different types and stages of the disease. This achievement promises to revolutionize early detection and personalized treatment strategies. Furthermore, CSIR-CCMB launched the Indian Breast Cancer Genomic Atlas (IBCGA), a pioneering initiative to map the genomes of nearly 1,000 breast cancer tumors across the country. This atlas will uncover molecular features unique to Indian breast cancer cases, enhancing clinical management and tailoring treatments to patient-specific needs.

For genetic disorders, CSIR-CCMB developed a rapid, affordable molecular test for sickle cell anaemia, a prevalent genetic disease in India affecting tribal and mainland populations. Using indigenously developed reagents, this test improves the accuracy and speed of detection, addressing a significant public health challenge in the country.

In neurodegenerative disease research, the CSIR-Institute of Microbial Technology (CSIR-IMTech) identified a molecule with promising potential to treat Parkinson's disease. Preliminary studies in mice demonstrated the molecule’s effectiveness, and researchers have filed international patents for four related molecules. These discoveries could pave the way for innovative therapies to combat Parkinson's, a condition with a growing burden globally and in India.

With these achievements, CSIR continues to push the boundaries of healthcare innovation, focusing on cost-effective and accessible solutions tailored to Indian needs. Headquartered in New Delhi, CSIR’s contributions in genomics, molecular biology, and disease research are positioning India as a leader in precision medicine and public health solutions.